Scott Requadt - 10 Sep 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)

Role
Chief Executive Officer, Director
Signature
/s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol
TRML
Transactions as of
10 Sep 2022
Net transactions value
$0
Form type
4
Filing time
13 Sep 2022, 16:30:40 UTC
Previous filing
02 Aug 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TALS Common Stock Award $0 +80,000 +16% $0.000000 590,189 10 Sep 2022 Direct F1, F2
holding TALS Common Stock 449,766 10 Sep 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
F2 Includes 1,509 shares previously acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F3 These shares are held by Requadt Family Limited Partnership. The Reporting Person has voting and dispositive power over the shares beneficially owned by Requadt Family Limited Partnership.